Piper Sandler Lifts Praxis Precision Medicines Price Target to $1,200 While Maintaining Overweight
Piper Sandler hiked its price target on Praxis Precision Medicines (PRAX) to $1,200 from $450 and reaffirmed an Overweight rating. The firm updated its model to include four programs and projects substantial peak U.S. sales by 2046, while Praxis prepares New Drug Applications for two lead candidates by mid-February 2026 and has completed a priced p…